You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ):CTLA-4抗體聯合PD-1抗體治療晚期宮頸癌的臨牀試驗獲批
格隆匯 07-29 19:36

格隆匯7月29日丨貝達藥業(300558.SZ)公佈,今日公司到國家藥品監督管理局(“NMPA”)籤發的《藥物臨牀試驗批准通知書》(通知書編號:2021LP01126),公司Agenus Inc.(NASDAQ: AGENAgenus”)共同申報的澤弗利單抗注射液(ZalifrelimabCTLA-4抗體)聯合巴替利單抗注射液(BalstilimabPD-1抗體)治療晚期宮頸癌的臨牀試驗已NMPA批准開展。

澤弗利單抗注射液是一種靶向於T細胞表面表達的細胞毒性 T 淋巴細胞相關抗原4(CTLA-4)的全人源單克隆抗體通過Agenus 的戰略合作,公司取得了巴替利單抗和澤弗利單抗在中國(包括香港、澳門和台灣)區域內單藥或聯用(包括聯合其它藥物)治療除膀胱內給藥外的所有腫瘤學和非腫瘤學適應症的獨家權利。巴替利單抗和澤弗利單抗是公司研發管線的重要補充,有助於公司探索開發管線產品的聯用治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account